News

Greater Bay Area International Clinical Trial Institute held a collaboration meeting with the LKS Faculty of Medicine of the University of Hong Kong and the Faculty of Medicine of the Chinese University of Hong Kong to have an in-depth exchange on advancing clinical trial collaboration on May 21, 2025. The three parties signed a Memorandum of Understanding on clinical trial collaboration after the meeting, marking a significant milestone in the development of clinical research in Hong Kong.

During the meeting, the GBAICTI Chief Executive Officer, Professor Bernard Cheung, had in-depth discussions with representatives of the two medical faculties on clinical trial collaboration. The two medical faculties are expected to launch more than 70 clinical trial projects in the coming year, covering innovative therapies in key areas including cancer, liver diseases, cardiovascular diseases, endocrine diseases, and rare diseases. The GBAICTI will provide comprehensive support, particularly in aspects such as co-ordinating multicentre cross-boundary clinical trials, connecting healthcare institutions across the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), and streamlining processes, to facilitate efficient implementation and execution of cross-boundary clinical trials. Moreover, the three parties will also strengthen talent training co-operation to further enhance Hong Kong's overall capability in clinical research.